Epigral Limited, India’s leading integrated chemical manufacturer, reported a challenging Q3 FY26 (ending December 31, 2025) with a 7 % YoY revenue decline to Rs. 602.68 crore, driven by a 62% YoY drop in Profit After Tax to Rs. 39.15 crore and an EBITDA margin contraction to 17%. Despite lower realizations, the company continues to invest in capacity expansion.

Commenting on the results, Maulik Patel, Chairman and Managing Director, Epigral said, “This quarter delivered marginal sequential top line growth. While demand softened before mid-November due to extended monsoon conditions, the market has strengthened notably since then, and we anticipate sustained positive momentum ahead. Margins in Q3 FY26 reflected temporary pressures from softer realizations on select products, elevated raw material costs, and inventory dynamics. With the improving market scenario, we anticipate positive outcomes starting Q4 FY26.

"Our capacity expansion projects for CPVC, Epichlorohydrin, and Wind Solar Hybrid Power Plant are progressing smoothly on schedule, set for timely commissioning. These initiatives will drive growth from FY27 onwards. We're also advancing new projects and look forward to sharing updates soon," commented Patel.

We remain committed to our journey of scalable, profitable growth—optimizing capital allocation, enhancing integration, and delivering lasting value for all stakeholders,” added Patel.

PVC Resin capacity will reach to 1, 50,000 TPA, by adding additional 75,000 TPA. Epichlorohydrin capacity will reach to 1, 00,000 TPA, by adding additional 50,000 TPA. Wind Solar hybrid power plant capacity will reach to 38.14 MW, by adding additional 19.80 MW. Epigral commissioned India’s 1st Chlorotoluenes Value Chain plant in March 2025.